The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

By P. Angulo, J. Hui, Giulio Marchesini, E. Bugianesi, J. George, G. Farrell, F. Enders, S. Saksena, A. Burt, J. Bida and 7 more. Hepatology, 2007

3,034 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/62cfbbe28c1c10d01fef01a276dc0c87f66d24de

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Epidemiology

In Hepatology

Citations in the corpus

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease (2017, background): “Characterized by excessive fat deposition in the liver that is not attributable to consumption of alcohol (4), the most common risk factors include obesity, insulin resistance and the features of metabolic syndrome (5).”
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018, background): “90 with 80% sensitivity and 90% specificity for detecting advanced fibrosis (bridging fibrosis or cirrhosis).((106)) This panel has been recently approved for commercial use in Europe, but is not available for clinical use in the United States.”
The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. (2013, background): “Studies suggest that the severity of insulin resistance is correlated with the likelihood of progression from benign steatosis to NASH and the development of fibrosis [6–9].”
Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. (2016, methodology): “Scoring Systems Based on a review of the literature, the following scores were calculated for each patient: FIB4 index [37]; NAFLD fibrosis score (NFS) [38]; aspartate aminotransferase (AST) to platelet ratio index (APRI) [39], AST-to- alanine transaminase (ALT) ratio (AAR), and the BARD score [40].”
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. (2015, methodology): “Previous studies have shown that simple non-invasive scores for fibrosis, such as the NAFLD fibrosis score and FIB-4, are effective in identifying patients with advanced fibrosis in NAFLD [28,33–36].”
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012, background): “90 with 80% sensitivity and 90% specificity for detecting advanced fibrosis.(71) Circulating levels of cytokeratin-18 (CK18) fragments have been investigated extensively as novel biomarkers for the presence of steatohepatitis in patients with NAFLD.”
Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years (2010, background): “l)–0.66×albumin (g/dl), where IFG = impaired fasting glucose.”